Overview
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
Eligibility
Inclusion Criteria:
- Adult participants ≥19 years of age
- Diagnosis of moderate-to-severe plaque psoriasis
- Candidate for phototherapy or systemic therapy
- Will begin deucravacitinib according to approved product label
Exclusion Criteria:
- Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
- Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)